CLYM

Based on Climb Bio, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Climb Bio do?

Climb Bio is a clinical-stage biotechnology company developing therapies for autoimmune-driven inflammatory diseases. Its lead candidate, budoprutug, is an anti-CD19 monoclonal antibody being studied in conditions such as systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy.

Does CLYM pay dividends?

No, Climb Bio does not pay a dividend. As a pre-revenue clinical-stage company, it reinvests all available capital into research and clinical development. Dividend income is not a realistic expectation for CLYM shareholders at this stage.

When does CLYM report earnings?

Climb Bio reports on a quarterly cadence, as required for US-listed public companies. Because it is pre-revenue, reports focus on cash runway and pipeline updates rather than traditional earnings. Check Climb Bio's investor relations page for the most current schedule.

Is CLYM a good stock to buy?

UQS Score rates CLYM as Poor overall. Quality, Moat, and Growth are all rated Weak, while Valuation is Elevated. The Risk pillar earns a Good label, which is a relative positive. Investors should weigh these factors carefully against their own risk tolerance before making any decision.

Is CLYM overvalued?

The UQS Valuation pillar for CLYM is rated Elevated, suggesting the current market price may not offer a comfortable margin of safety relative to the company's development-stage fundamentals. Pre-revenue biotechs often carry premium valuations based on pipeline potential rather than current financials.

How does CLYM compare to its competitors?

Compared to peers like Rigel Pharmaceuticals, which has approved commercial products, Climb Bio is at an earlier stage with a narrower pipeline. Rivals such as Zevra Therapeutics and ProKidney Corp. pursue different therapeutic modalities, making direct comparisons complex. The full UQS competitor breakdown is available to Pro members.

What is CLYM's market cap bracket?

Climb Bio is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and liquidity risk compared to mid- or large-cap peers, which is common for clinical-stage biotechnology firms.

Who founded Climb Bio?

Climb Bio was incorporated in 2018 and operated under the name Eliem Therapeutics before rebranding in October 2024. Detailed founding information, including leadership history, is publicly available through the company's SEC filings and investor relations materials.

Is CLYM a long-term quality investment?

As a long-term quality indicator, the UQS Score rates CLYM as Poor. Weak scores across Quality, Moat, and Growth suggest the company has not yet established the durable fundamentals typically associated with long-term compounders. Clinical success could change this picture, but current metrics reflect significant uncertainty.

What is the main competitive advantage of Climb Bio?

Climb Bio's potential advantage lies in its focus on budoprutug's mechanism — targeting CD19-positive B cells across multiple autoimmune indications. However, the UQS Moat pillar is rated Weak, reflecting that no durable competitive advantage has been established at this stage of development.

What sector does CLYM belong to?

Climb Bio operates in the Healthcare sector, specifically within biotechnology. It focuses on the autoimmune and inflammatory disease sub-segment, which includes conditions with significant unmet medical need and active drug development competition.

Is CLYM a growth stock or value stock?

Based on UQS pillar labels, CLYM does not fit cleanly into either category. The Growth pillar is rated Weak and Valuation is Elevated, meaning the stock carries a premium price without demonstrated growth metrics to support it — a profile more speculative than either classic growth or value.

Climb Bio, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.

Climb Bio, Inc. faces growth headwinds with declining or stagnant revenue trends.

Climb Bio, Inc. maintains a reasonable risk profile with manageable debt levels.

Climb Bio, Inc. appears expensively valued relative to its fundamentals and growth prospects.

Climb Bio, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CLYM.

The UQS (Unified Quality Score) for Climb Bio, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Climb Bio, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Climb Bio, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.